Meral Beksac
Ankara Üniversitesi
H-index: 65
Asia-Turkey
Top articles of Meral Beksac
IN VIVO AND IN VITRO EFFECTS OF CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELL (HSPC) EXPANSION USING VALPROIC ACID AND/OR NICOTINAMIDE
Current Research in Translational Medicine
2024/3/1
Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases
British Journal of Haematology
2024/3
Ali Ünal
H-Index: 21
Meral Beksac
H-Index: 42
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Clinical Lymphoma Myeloma and Leukemia
2024/3/1
Meral Beksac
H-Index: 42
Paul Richardson
H-Index: 12
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect …
Leukemia & Lymphoma
2024/2/10
Meral Beksac
H-Index: 42
Sachin Patel
H-Index: 38
Latest Research
Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells
Chemical Biology & Drug Design
2024/2
Bekir Cetintav
H-Index: 3
Meral Beksac
H-Index: 42
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma …
Bone Marrow Transplantation
2024/1/31
Meral Beksac
H-Index: 42
Xavier Poiré
H-Index: 19
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
New England Journal of Medicine
2024/1/25
Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study
Frontiers in Cardiovascular Medicine
2024
P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN …
HemaSphere
2023/8/1
Aleksandra Sretenovic
H-Index: 7
Maria Roussou
H-Index: 22
Meral Beksac
H-Index: 42
Evangelos Terpos
H-Index: 61
Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus …
Blood
2023/11/28
Andrew Spencer
H-Index: 23
Irwindeep Sandhu
H-Index: 16
Dean Smith
H-Index: 13
Meral Beksac
H-Index: 42
Liang Li
H-Index: 4
P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
HemaSphere
2023/8/1
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
Bone marrow transplantation
2023/8
Meral Beksac
H-Index: 42
Kim Orchard
H-Index: 19
HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma
Chemical Biology & Drug Design
2023/8
Meral Beksac
H-Index: 42
Phase 3 randomized study of daratumumab (DARA)+ bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM …
Blood
2023/11/21
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE
Acta Haematologica
2013/4/1
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study
European Journal of Haematology
2023/8
The Many Faces of Multiple Myeloma (MM)
Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
2023/7/27
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies …
Bone Marrow Transplantation
2023/11
Meral Beksac
H-Index: 42
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended …
The Lancet Haematology
2023/10/1
Co-Authors
